T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024GlobeNewsWire • Wednesday
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.GlobeNewsWire • 03/28/24
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesGlobeNewsWire • 03/20/24
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesGlobeNewsWire • 03/19/24
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelGlobeNewsWire • 03/18/24
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/15/24
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityGlobeNewsWire • 02/15/24
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaGlobeNewsWire • 02/15/24
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria PanelGlobeNewsWire • 02/12/24
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024GlobeNewsWire • 02/07/24
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics PrizeGlobeNewsWire • 02/07/24
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia PatientsGlobeNewsWire • 01/18/24
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric TestingGlobeNewsWire • 01/03/24
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumGlobeNewsWire • 11/03/23